University Medical Center Schleswig Holstein

Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Pain, European Association for the Study of the Liver, TRIBUTE, Trial of the century, University Medical Center, Tildrakizumab, BME, Venereology, Safety, ALM, Congress, University Medical Center Schleswig Holstein, Itch, Quality of life (healthcare), Almirall, Pros, RCT, Grammatical mood, Skin, Patient, Quality of life, Medical device, Medical imaging, Psoriasis, Dermatology

Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2

Key Points: 
  • Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2
    During the congress held in Berlin from October 11th to 14th, Almirall presented 12 posters highlighting new data on tildrakizumab in patients with moderate-to-severe plaque psoriasis.
  • Additionally, the symposium titled “New Landmark on Psoriasis treatment: the POSITIVE study”, chaired by Prof. Dr. Matthias Augustin and Prof. Dr. Ulrich Mrowietz, will explore the impact of tildrakizumab on physical, social and mental wellbeing in psoriasis.
  • Understanding the broader implications of psoriasis is a significant advance in our field and underlines the importance of a holistic approach to its treatment.
  • These data demonstrate the consolidated effectiveness and safety of tildrakizumab in treating plaque psoriasis and patients’ overall wellbeing.

EXOSOMM Looks to the Benefits of Mother's Milk to Bring New Bioactive Ingredient for Medical Food Space

Retrieved on: 
Wednesday, May 3, 2023
Nanoparticle, Obesity, Food, Diabetes, IBD, Israeli cuisine, Infection, 3D, Mammal, Food safety, Exosome, Inflammatory bowel disease, Quality of life, MicroRNA, Cheese, Research, Inflammation, RNA, DSM-IV codes, Virtue, Crohn's disease, Milk, Sheep, Patient, Child, Immune system, Hadassah Medical Center, Growth, IMI Galil, Health, University Medical Center Schleswig Holstein, Vaccine, Dairy, Dietary supplement, MD, Colitis

JERUSALEM, May 3, 2023 /PRNewswire/ -- BioFoodTech start-up EXOSOMM, Ltd., has explored the natural mechanisms inherent in human breastmilk to create a novel bioactive ingredient that can potentially support millions of adults with inflammatory disorders. Based on its scientific findings EXOSOMM developed an innovative technology that isolates exosomes—natural particles in maternal milk that play an important role in the healthy development of the immune system.

Key Points: 
  • EXOSOMM upcycles byproducts of the traditional cheese making process to create this potent functional ingredient.
  • While still a young start-up, it has already reached commercial production capacity of its patent-protected exosomes for the medical food space.
  • Moreover, it was important for us to derive the milk benefits without exerting any burden on milk production.
  • EXOSOMM has been selected as a finalist in the Most Innovative Nutraceutical Ingredient category at the upcoming Vitafoods Startup Innovation Challenge 2023.

OSE Immunotherapeutics Presents Clinical and Preclinical Data from its Immuno-Oncology Portfolio

Retrieved on: 
Tuesday, April 18, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Myelocyte, Kiel University, Acute lymphoblastic leukemia, CD47, Partnership, AACR, Schleswig-Holstein, CD127, IL-7, ALL, University Medical Center, Myeloid-derived suppressor cell, Inflammation, Survival, Cancer, Phagocytosis, American Association for Cancer Research, University Medical Center Schleswig Holstein, Head, Prognosis, Biomarker, Immunotherapy, Neck, Cetuximab, Ulcerative colitis, Boehringer Ingelheim, CD8, Patient, Hematology, T-ALL, ISIN, Mnemos EP, OSE, Tumor microenvironment, Pharmaceutical industry, Vaccine, Medical imaging

In addition, preclinical characterization data on CLEC-1 (new myeloid immune checkpoint) binding mechanism will also be presented on April 19.

Key Points: 
  • In addition, preclinical characterization data on CLEC-1 (new myeloid immune checkpoint) binding mechanism will also be presented on April 19.
  • Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very pleased to share our latest scientific advances with the leading international cancer scientific community.
  • The escalation Phase 1 clinical trial data on selective SIRPα antagonist BI 765063 showed preliminary clinical efficacy results in monotherapy and in combination with PD1 inhibitor ezabenlimab in patients with advanced solid tumors.
  • Two clinical studies are ongoing in inflammatory diseases: a phase 2a study conducted in primary Sjögren’s syndrome by Servier and a Phase 2 study conducted in ulcerative colitis by OSE Immunotherapeutics.

Healthcare Veteran John O'Reilly Joins GATC Health's Advisory Board

Retrieved on: 
Wednesday, October 19, 2022
Health, Time, Nevada Gaming Commission, Risk, Medicine, GATC, Business administration, Science, Reno 1868 FC, Organization, Air force, Strategic planning, United, Secretary of State of Nevada, University Medical Center, Multimedia, Partnership, Artificial intelligence, Technology, University, Human body, Company, Drug discovery, University of Nevada, Reno, Contract, University Medical Center Schleswig Holstein, Advisory board, Master, Saint Louis University, Bachelor of Science in Human Biology, View, Leadership, Pharmaceutical industry, Management

IRVINE, Calif., Oct. 19, 2022 /PRNewswire/ -- GATC Health ("GATC" or "the Company"), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that John O'Reilly has joined its Advisory Board.

Key Points: 
  • IRVINE, Calif., Oct. 19, 2022 /PRNewswire/ -- GATC Health ("GATC" or "the Company"), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that John O'Reilly has joined its Advisory Board.
  • O'Reilly currently serves on the UCLA Health System Board and as Chairman of the University Medical Center of Southern Nevada Governing Board in Las Vegas.
  • Previously, O'Reilly served as the Chairman of the Nevada Medical Center, a non-profit entity privately funded to develop and acquire cutting-edge healthcare innovations.
  • "John's decorated career brings an impressive range of expertise to GATC Health's Advisory Board," said Jeff Moses, President of GATC Health.

omniQ receives an Approximately $10 Million Purchase Agreement for Intelligent Healthcare Carts (IHC) from Israel’s Ministry of Health.

Retrieved on: 
Monday, October 10, 2022
U.S. Securities and Exchange Commission, Data collection, Securities Act of 1933, Health care, Computer, Transport, Growth, Community Tool Box, NASDAQ, COVID-19, Patient, Securities Exchange Act of 1934, Hospital, IHC, Investment, Ministry of Health (Saudi Arabia), Risk, University Medical Center Schleswig Holstein, Fortune 500, Technology, Airport, Automation, Private Securities Litigation Reform Act, Company, SALT, Device file, CEO, Food, Artificial intelligence, Government, Ministry, GLOBE, Forward-looking statement, Ministry of Finance and Economic Planning (Ghana), Traffic park, Solution, School, Medical device, Medicine, Health

A five year supply agreement for Intelligent Healthcare Carts to be deployed in over 20 Prestigious Medical Centers.

Key Points: 
  • A five year supply agreement for Intelligent Healthcare Carts to be deployed in over 20 Prestigious Medical Centers.
  • The Ministry of Health order follows the previously announced award for $11M with the Ministry of Finance.
  • As the pioneer in IHCs, Dangot now provides computerized solutions with smart integrated systems to the majority of hospitals throughout Israel.
  • This technology plays a crucial role in the patient experience and assists the healthcare provider in making accurate treatment decisions.

Lenire®, the treatment device shown to reduce tinnitus symptoms in 95% of patients, is now available in Hungary

Retrieved on: 
Thursday, September 29, 2022
Safety, Brain, Prevalence, University of Debrecen, Tinnitus, Partnership, Hungarians, Patient, CEO, Sound, Perception, Research, Tongue, University, University Medical Center Schleswig Holstein, Oxford Brookes University, Medicine, Pharmaceutical industry, Dentistry, Medical device, Audiology, Lancet

Lenire is a bimodal neuromodulation device which has shown in analysis of real-world patients and multiple large-scale clinical trials to reduce the severity of tinnitus symptoms.

Key Points: 
  • Lenire is a bimodal neuromodulation device which has shown in analysis of real-world patients and multiple large-scale clinical trials to reduce the severity of tinnitus symptoms.
  • It found that prevalence of any tinnitus was 14.7%i, which could mean that 1.4 million Hungarians experience the condition.
  • Through this distribution agreement, Tinnitus Klinika's specialist team has exclusive licence from Neuromod to provide Lenire throughout Hungary to suitable patients for the treatment of their tinnitus.
  • "I'm delighted to work with Tinnitus Klinika tomake Lenire available to people living with tinnitus in Hungary.

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

Retrieved on: 
Monday, September 5, 2022
BRCA1, BRCA2, Patient, Cancer, Myriad Genetics, University Medical Center Schleswig Holstein, Research, Netherlands Cancer Institute, Agriculture, Armed Forces Institute of Pathology, Oncology, Reproductive health, NASDAQ, HRD, SAN, YouTube, NGS, Pathology, Precision medicine, R, Large-cell lung carcinoma, Bayer, CGP, ESMO, LinkedIn, DNA, Particle-size distribution, Workflow, Illumina, Inc., Genome, PARP, Allegheny Health Network, Instagram, List of pathologists, DNA repair, European Society for Medical Oncology, Genetics, Immunotherapy, TSO, NSCLC, Twitter, Merck, 2021 Essex County Council election, Biomarker, Neoplasm, Technical University of Munich, Institute, Liquid biopsy, Ovarian cancer, GIS, Genomics, Health, University Medical Center Utrecht, Institute of technology, Medical imaging, Pharmaceutical industry, EU, Illumina, Facebook

SAN DIEGO, Sept. 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the upcoming presentation of multiple oncology research abstracts at this year's European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina's oncology assays for cancer research and patient care. 

Key Points: 
  • The abstractsunderscore the value of next-generation sequencing (NGS) and Illumina's oncology assays for cancer research and patient care.
  • "There is growing evidence that using comprehensive genomic profiling that includes pan-cancer and immunotherapy biomarkers can identify the greatest number of patients who most benefit from targeted therapy."
  • HRD status has emerged as an important biomarker in tumors that have high levels of DNA damage, such as ovarian cancer.
  • However, to enable genomic profiling of ovarian cancer tumors with indications for PARP inhibitors and predict response to these treatments, labs must reliably assess HRD status in those tumors.

Fairtility Launches AI Academy to Demystify Use of Artificial Intelligence in Fertility Care

Retrieved on: 
Tuesday, July 26, 2022
Gynaecology, Knowledge, Education, Clinical research, Ben-Gurion University of the Negev, Industry, Obstetrics, Twitter, Ethics, CEO, Annual general meeting, Infertility, Human Reproduction (journal), University Medical Center Schleswig Holstein, Associate, ESHRE, Engineering, Weill Cornell Medical College in Qatar, Adoption, European Society for Primary Immunodeficiencies, Bachelor of Engineering, Technology, Information system, LinkedIn, Patient, Reproductive medicine, Digital health, Department, IVF, Entrepreneurship, Health care, TEL, Medical device, Fertility, Software, AI, Embryology

TEL AVIV, Israel, July 26, 2022 /PRNewswire/ -- Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the launch of the AI Academy, a new educational platform that will host healthcare and technology experts to engage the IVF community in the conversation around the responsible adoption of AI innovation in IVF care. 

Key Points: 
  • Fairtility launched the AI Academy at the European Society of Human Reproduction and Embryology (ESHRE) 38th Annual Meeting, which took place in Milan, Italy, July 3-6.
  • Dr. Gerard Letterie, a leader in reproductive endocrinology and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.
  • "Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.
  • For further information or to register for AI Academy, visit: www.fairtility.com/AIAcademy
    Fairtility is powering in vitro fertilization (IVF) through transparent AI to improve outcomes.

MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference

Retrieved on: 
Wednesday, April 13, 2022
CEO, Wilhelmina, Poster, PLOS One, CE marking, Pediatrics, University Medical Center Utrecht, CRP, MD, Lancet, Internet meme, Department, Doctor of Philosophy, University Medical Center Schleswig Holstein, Patient, Biomarker, Sepsis, Ministry, Maimonides Medical Center, Conference, Technology, Infection, Bureau of Oceans and International Environmental and Scientific Affairs, Solution, Fever, Assistant, Physician, FDA, European Journal of Clinical Microbiology & Infectious Diseases, Chairperson, Emergency medicine, Congress, Pharmaceutical industry, Vaccine, Health, European, Pneumonia

MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32ndEuropean Congress of Clinical Microbiology and Infectious Diseases Conference

Key Points: 
  • MeMed to host integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32ndEuropean Congress of Clinical Microbiology and Infectious Diseases Conference
    Haifa, Israel; Boston, MA April 13, 2022 MeMed, a leader in host response technologies, is pleased to announce that it will present their technology at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022.
  • Clinical key opinion leaders will present clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract.
  • Matthew Faron, PhD, Assistant Professor of Pathology Medical College of Wisconsin, will present a poster on MeMed BV performance validation data.
  • The MeMed BV test has received FDA Clearance, CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

SciBase Barrier technology part of major immunodermatology project

Retrieved on: 
Wednesday, March 23, 2022
Dutch Research Council, Biomarker, Skin, University, Meuro, SCIB, Research, Hospital, Data analysis, Consortium, University Medical Center Schleswig Holstein, Disease management, NWO, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology

NGID is a nationwide, large-scale project to unravel novel biomarkers for six different skin diseases.

Key Points: 
  • NGID is a nationwide, large-scale project to unravel novel biomarkers for six different skin diseases.
  • The importance of the skin barrier in diseases such as atopic dermatitis is well known, but until now it has not been possible to evaluate the barrier in routine clinical practice.
  • The inclusion of these SciBase products in this consortium is a testament to the robust diagnostic potential of the SciBase technology.
  • The opportunity for SciBase is to become an integral part of personalized atopic dermatitis management, and with the very high numbers of patients affected, this is one of the most significant opportunities for SciBase to date", says Simon Grant CEO SciBase.